Seres Therapeutics, Inc. current report, 22 June 2023

Full document

Seres Therapeutics, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports the results of the Annual Meeting of Stockholders held by Seres Therapeutics, Inc. on June 22, 2023. The filing details the voting outcomes for five proposals presented to shareholders.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting results.

Material Changes and Voting Results

A total of 105,574,736 shares were present at the meeting, representing approximately 82.59% of outstanding common stock. All five proposals were approved:

  • Item 1 (Director Election): Three Class II directors were elected. Stephen A. Berenson received 66,654,686 votes FOR (with 25,911,953 withheld). Richard N. Kender and Claire M. Fraser, Ph.D., received over 92 million votes FOR each with minimal withholdings.
  • Item 2 (Auditor Ratification): PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm with 105,266,043 votes FOR.
  • Item 3 (Executive Compensation): The advisory vote on named executive officer compensation was approved with 91,849,150 votes FOR.
  • Item 4 (Authorized Shares): An amendment to increase authorized common stock from 200,000,000 to 240,000,000 shares was approved with 103,795,039 votes FOR.
  • Item 5 (Adjournment): Approval to adjourn the meeting to solicit additional proxies if necessary was granted with 102,104,854 votes FOR.

Guidance, Outlook, and Risks

The filing does not provide management commentary, financial guidance, outlook, or specific risk factors. It is a procedural report of shareholder voting outcomes.

Key Facts for Investor Verification

  • Verify the updated authorized share count of 240,000,000 following the approval of Item 4.
  • Note the significant number of votes withheld for director Stephen A. Berenson (25.9 million) compared to the other nominees.
  • Confirm the ratification of PricewaterhouseCoopers LLP as the auditor for the fiscal year ending December 31, 2023.
  • Review the Definitive Proxy Statement filed on April 25, 2023, for detailed background on the proposals.